Comparative Efficacy and Safety of Three Current Clinical Treatments for Girls with Central Precocious Puberty: A Network Meta-Analysis

医学 荟萃分析 中枢性早熟 儿科 性早熟 内科学 激素
作者
Qiushi Gu,Yi Luo,Jun Ye,Xiaoping Shen
出处
期刊:Endocrine Practice [Elsevier]
卷期号:25 (7): 717-728 被引量:13
标识
DOI:10.4158/ep-2019-0008
摘要

Objective: The optimal treatment for girls with central precocious puberty (CPP) is unknown. We conducted a network meta-analysis to evaluate the efficacy and safety of existing treatments to provide credible clinical guidelines. Methods: We compared gonadotropin-releasing hormone analogue (GnRHa) therapy, GnRHa plus growth hormone (GH) combination therapy, and no-treatment therapy for girls with CPP by performing an electronic search for studies in PubMed, Embase, Chinese National Knowledge Infrastructure databases, and Wanfang Data from their inception until September 30, 2018. Six outcomes, including bone maturation ratio, final height, final height compared with target height, growth velocity, height gain, and gain in predicted adult height (ΔPAH), were expressed as the mean difference with 95% confidence interval. The surface under the cumulative ranking curve (SUCRA) value illustrated the rank probability of each treatment under different outcomes. Results: Twenty-two studies with 1,268 patients were included. GnRHa plus GH had the best performance on final height, final height compared with target height, growth velocity, height gain, and ΔPAH, with the highest SUCRA values of 0.919, 0.975, 0.909, 0.999, and 0.957, respectively. For bone maturation ratio, GnRHa ranked the highest, with a SUCRA value of 0.663. No severe adverse effects were reported. Conclusion: For girls with CPP, GnRHa plus GH had the highest probability of being the optimal therapy for improving final height, and no severe adverse effects were reported. Abbreviations: BMI = body mass index; CI = confidence interval; CPP = central precocious puberty; GH = growth hormone; GnRHa = gonadotropin-releasing hormone analogue; HPG = hypothalamic-pituitary-gonadal; LH = luteinizing hormone; NMA = network meta-analysis; PAH = predicted adult height; PCOS = polycystic ovary syndrome; RCT = randomized controlled trial; SUCRA = surface under the cumulative ranking curve.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
卜懂得完成签到,获得积分10
刚刚
科研工作者完成签到,获得积分10
刚刚
魔幻的访云完成签到 ,获得积分10
1秒前
1秒前
1秒前
NexusExplorer应助xly采纳,获得10
2秒前
余德熙发布了新的文献求助10
3秒前
smile发布了新的文献求助20
3秒前
周周周完成签到,获得积分10
4秒前
4秒前
BWY完成签到,获得积分10
6秒前
徒tu发布了新的文献求助10
7秒前
7秒前
7秒前
7秒前
刘斌发布了新的文献求助10
7秒前
8秒前
sekiro完成签到,获得积分10
8秒前
reason完成签到,获得积分10
9秒前
10秒前
11秒前
顾矜应助linda采纳,获得10
11秒前
等你下课发布了新的文献求助10
11秒前
12秒前
xxxlglm发布了新的文献求助10
13秒前
可爱的函函应助哈哈哈采纳,获得10
14秒前
xly发布了新的文献求助10
15秒前
清爽谷秋完成签到,获得积分10
15秒前
MM完成签到,获得积分10
15秒前
16秒前
优雅的冰岚完成签到,获得积分10
16秒前
hygge完成签到 ,获得积分10
18秒前
18秒前
科研通AI2S应助EKKOO采纳,获得10
19秒前
哈哈悦完成签到,获得积分10
19秒前
19秒前
万能图书馆应助科学家采纳,获得10
20秒前
cyan发布了新的文献求助10
21秒前
不安初彤完成签到,获得积分10
21秒前
缓慢凝梦发布了新的文献求助10
22秒前
高分求助中
Evolution 10000
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
юрские динозавры восточного забайкалья 800
Diagnostic immunohistochemistry : theranostic and genomic applications 6th Edition 500
Chen Hansheng: China’s Last Romantic Revolutionary 500
China's Relations With Japan 1945-83: The Role of Liao Chengzhi 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3149194
求助须知:如何正确求助?哪些是违规求助? 2800255
关于积分的说明 7839329
捐赠科研通 2457827
什么是DOI,文献DOI怎么找? 1308138
科研通“疑难数据库(出版商)”最低求助积分说明 628428
版权声明 601706